Differential Effects of EGFR Ligands on Endocytic Sorting of the Receptor

Abstract

Endocytic downregulation is a pivotal mechanism turning off signalling from the EGF receptor (EGFR). It is well established that whereas EGF binding leads to lysosomal degradation of EGFR, transforming growth factor (TGF)‐α causes receptor recycling. TGF‐α therefore leads to continuous signalling and is a more potent mitogen than EGF. In addition to EGF and TGF‐α, five EGFR ligands have been identified. Although many of these ligands are upregulated in cancers, very little is known about their effect on EGFR trafficking. We have compared the effect of six different ligands on endocytic trafficking of EGFR. We find that, whereas they all stimulate receptor internalization, they have very diverse effects on endocytic sorting. Heparin‐binding EGF‐like growth factor and Betacellulin target all EGFRs for lysosomal degradation. In contrast, TGF‐α and epiregulin lead to complete receptor recycling. EGF leads to lysosomal degradation of the majority but not all EGFRs. Amphiregulin does not target EGFR for lysosomal degradation but causes fast as well as slow EGFR recycling. The Cbl ubiquitin ligases, especially c‐Cbl, are responsible for EGFR ubiquitination after stimulation with all ligands, and persistent EGFR phosphorylation and ubiquitination largely correlate with receptor degradation.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 38

1. 1.

   Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp.Cell Res. 2003;284:2-13.

   Not in our library10.1016/s0014-4827(02)00105-2

2. 2.

   Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De LA, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer: an overview. Curr.Drug Targets. 2005;6:243-257.

   Not in our library10.2174/1389450053765879

3. 3.

   Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol. 2008;19:73-80.

   Not in our library10.1093/annonc/mdm431

4. 4.

   Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res. 2001;61:6227-6233.

   Not in our library

5. 5.

   Roepstorff K, Grøvdal LM, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem.Cell Biol. 2008;129:563-578.

   Not in our library10.1007/s00418-008-0401-3

6. 6.

   Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, et al. Cbl-mediated ubiquitylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem. 2003;278:28950-28960.

   Not in our library10.1074/jbc.m304474200

7. 7.

   Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol. 2002;156:843-854.

   Not in our library10.1083/jcb.200106056

8. 8.

   Raiborg C, Rusten TE, Stenmark H. Protein sorting into multivesicular endosomes. Curr Opin Cell Biol. 2003;15:446-455.

   Not in our library10.1016/s0955-0674(03)00080-2

9. 9.

   Ebner R, Derynck R. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul. 1991;2:599-612.

   Not in our library10.1091/mbc.2.8.599

10. 10.

    Decker SJ. Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem Biophys Res Commun. 1990;166:615-621.

    Not in our library10.1016/0006-291x(90)90853-f

11. 11.

    Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem. 1998;273:13819-13827.

    Not in our library10.1074/jbc.273.22.13819

12. 12.

    Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785:232-265.

    Not in our library10.1016/j.bbcan.2008.01.001

13. 13.

    Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res. 2000;20:91-95.

    Not in our library

14. 14.

    Sorkin A, Krolenko S, Kudrjavtceva N, Lazebnik J, Teslenko L, Soderquist AM, Nikolsky N. Recycling of epidermal growth factor-receptor complexes in A431 cells: identification of dual pathways. J Cell Biol. 1991;112:55-63.

    Not in our library10.1083/jcb.112.1.55

15. 15.

    Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 2008;15:209-219.

    Not in our library10.1016/j.devcel.2008.06.012

16. 16.

    Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 1999;447:227-231.

    Not in our library10.1016/s0014-5793(99)00283-5

17. 17.

    Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ. Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science. 1989;243:1074-1076.

    Not in our library10.1126/science.2466334

18. 18.

    Oksvold MP, Skarpen E, Lindeman B, Roos N, Huitfeldt HS. Immunocytochemical localization of Shc and activated EGF receptor in early endosomes after EGF stimulation of HeLa cells. J Histochem Cytochem. 2000;48:21-33.

    Not in our library10.1177/002215540004800103

19. 19.

    Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2001;2:107-117.

    Not in our library10.1038/35052055

20. 20.

    Baldys A, Gooz M, Morinelli TA, Lee MH, Raymond JR, Luttrell LM, Raymond JR. Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry. 2009;48:1462-1473.

    Not in our library10.1021/bi801771g

21. 21.

    Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998;12:3663-3674.

    Not in our library10.1101/gad.12.23.3663

22. 22.

    Jiang X, Huang F, Marusyk A, Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell. 2003;14:858-870.

    Not in our library10.1091/mbc.e02-08-0532

23. 23.

    Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 2002;21:303-313.

    Not in our library10.1093/emboj/21.3.303

24. 24.

    Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029-1040.

    Not in our library10.1016/s1097-2765(00)80231-2

25. 25.

    Huang F, Sorkin A. Growth factor receptor binding protein 2-mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell. 2005;16:1268-1281.

    Not in our library10.1091/mbc.e04-09-0832

26. 26.

    Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, Pierce JH, Lipkowitz S. cbl-b inhibits epidermal growth factor receptor signaling. Oncogene. 1999;18:1855-1866.

    Not in our library10.1038/sj.onc.1202499

27. 27.

    Grøvdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res. 2004;300:388-395.

    Not in our library10.1016/j.yexcr.2004.07.003

28. 28.

    Alwan HA, van Zoelen EJ, van Leeuwen JE. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem. 2003;278:35781-35790.

    Not in our library10.1074/jbc.m301326200

29. 29.

    Hayashi T, Sakamoto S. Radioimmunoassay of human epidermal growth factor–hEGF levels in human body fluids. J Pharmacobiodyn. 1988;11:146-151.

    Not in our library10.1248/bpb1978.11.146

30. 30.

    Grau M, Rodriguez C, Soley M, Ramirez I. Relationship between epidermal growth factor in mouse submandibular glands, plasma, and bile: effects of catecholamines and fasting. Endocrinology. 1994;135:1854-1862.

    Not in our library10.1210/endo.135.5.7956907

31. 31.

    Beardmore JM, Richards RC. Concentrations of epidermal growth factor in mouse milk throughout lactation. J Endocrinol. 1983;96:287-292.

    Not in our library10.1677/joe.0.0960287

32. 32.

    Gann PH, Chatterton R, Vogelsong K, Grayhack JT, Lee C. Epidermal growth factor-related peptides in human prostatic fluid: sources of variability in assay results. Prostate. 1997;32:234-240.

    Not in our library10.1002/(sici)1097-0045(19970901)32:4<234::aid-pros2>3.0.co;2-j

33. 33.

    Mullin JM. Epithelial barriers, compartmentation, and cancer. Sci.STKE. 2004;2004:e2.

    Not in our library10.1126/stke.2162004pe2

34. 34.

    Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De LA, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005;6:243-257.

    Not in our library10.2174/1389450053765879

35. 35.

    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.

    Not in our library10.1056/nejmoa033025

36. 36.

    Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.

    Not in our library10.1200/jco.2004.10.182

37. 37.

    Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237.

    Not in our library10.1200/jco.2006.10.5437

38. 38.

    Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Janne PA. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008;14:6963-6973.

    Not in our library10.1158/1078-0432.ccr-08-0957

Cited by papers we hold 9

• Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression · 2022
  No notice
• Emerging functions of the EGFR in cancer · 2017
  No notice
• Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model” · 2017
  No notice
• Integrin α6β4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation · 2017
  Not checked
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways · 2017
  No notice
• EGF receptor trafficking: consequences for signaling and cancer · 2014
  No notice
• The Mysterious Ways of ErbB2/HER2 Trafficking · 2014
  No notice
• Sonic Hedgehog modulates EGFR dependent proliferation of Neural Stem Cells during late mouse embryogenesis through EGFR Transactivation. · 2013
  Not checked
• Internalization Mechanisms of the Epidermal Growth Factor Receptor after Activation with Different Ligands · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.